Adjunctive Therapy of Exenatide or Sitagliptin to Insulin Glargine in Type 2 Diabetes

What this study is testing ClinicalTrials.gov NCT00971659 ↗

Description as written by the study sponsor.

This study investigated a 4-week adjunctive therapy of either a GLP-1 analog (exenatide), or a DPP-4 inhibitor (sitagliptin), given to a basal insulin analog (insulin glargine), and their effect on blood glucose control, versus insulin glargine alone as active comparator in type 2 diabetes.

Treatments tested

• insulin glargine + exenatide + preexisting metformin also known as Lantus, Byetta Drug

  insulin glargine once daily subcutaneously over 4 weeks, dose adjustment according to a treat-to-target algorithm, exenatide 5ug twice daily subcutaneously for 2 weeks, then 10ug twice daily for 2 weeks, continuation of preexisting metformin

• insulin glargine + sitagliptin + preexisting metformin also known as Lantus, Januvia Drug

  insulin glargine once daily subcutaneously over 4 weeks, dose adjustment according to a treat-to-target algorithm, sitagliptin 100 mg once daily in the morning over 4 weeks, continuation of preexisting metformin

• insulin glargine + preexisting metformin also known as Lantus Drug

  insulin glargine once daily subcutaneously over 4 weeks, continuation of preexisting metformin